TransMedics Group Inc
NASDAQ: TMDX · HEALTHCARE · MEDICAL DEVICES
Updated 2026-04-29
TransMedics Group Inc (TMDX) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for TMDX.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
TMDX historical valuation range
Where current P/E sits in TMDX's own 5Y range.
TMDX intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
TMDX valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 20.24x
P/S Ratio — History
Current: 5.62x
Is TMDX overvalued in 2026?
TransMedics Group Inc (TMDX) currently trades at $98.57 per share with a market capitalization of $3,405,018,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 64/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 20.2x, below its 5-year median of 24.8x.
Looking at its own history, TMDX is currently trading cheaper than 91% of the last 5Y on P/E. This places it in the 9th percentile of its historical range, a level that has historically coincided with attractive entry points.
Our discounted cash flow model estimates TMDX's intrinsic value at $308.61 per share, against the current market price of $98.57. This implies a margin of safety of +56.81%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 4/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: TMDX trades at a fair valuation on our framework, with a Smart Value Score of 64/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is TMDX overvalued in 2026?
Based on a Smart Value Score of 64/100, TMDX is fairly valued. Price reasonably reflects current fundamentals with limited cushion in either direction.
What is TMDX's fair value?
Our DCF model estimates TMDX's intrinsic value at $308.61 per share, versus the current price of $98.57. This produces a margin of safety of +56.81%.
What P/E ratio does TMDX trade at?
TMDX trades at a P/E of 20.2x on trailing twelve-month earnings, compared to its 5-year median of 24.8x.
Is TMDX a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 64/100 reflects the combined read on growth, quality, and price. The profile is balanced. Best suited for investors with an existing thesis.
How does TMDX's valuation compare to its history?
On P/E, TMDX currently sits in the 9th percentile of its own 5Y range. That is historically cheap relative to where it has traded over the period.
What is TMDX's Smart Value Score?
TMDX's Smart Value Score is 64/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.